Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage
Study on the Safety and Efficacy of Non-Invasive Transcranial Doppler Ultrasound in Promoting Hematoma Clearance for Intracerebral Hemorrhage
Beijing Tiantan Hospital
86 participants
Dec 12, 2025
INTERVENTIONAL
Conditions
Summary
Intracerebral hemorrhage (ICH) is one of the stroke subtypes with the highest global rates of disability and mortality, accounting for 15%-20% of all strokes. Currently, there is a lack of evidence-based interventions for ICH, with treatment primarily relying on supportive care. There is an urgent clinical need to explore new strategies and technologies. The investigators hypothesize that for ICH patients, best medical treatment combined with a non-invasive ultrasonic scalpel (ultrasound Doppler flow analyzer) may be superior to best medical treatment alone. The primary objective of this study is to determine the safety and efficacy of the non-invasive ultrasonic scalpel in promoting hematoma clearance in ICH patients.
Eligibility
Inclusion Criteria7
- Age 18 to 80 years;
- Spontaneous intracerebral hemorrhage (ICH);
- Supratentorial ICH;
- Hematoma volume <30 mL (calculated using the ABC/2 method);
- Glasgow Coma Scale (GCS) score >9 at randomization;
- Time from onset to randomization: 48-72 hours;
- Patient and/or legal representative provides informed consent.
Exclusion Criteria17
- Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders).
- Hemorrhage located in the infratentorial region.
- Hemorrhage confined primarily to the ventricular system.
- Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs).
- Severe cardiac dysfunction (NYHA Class III or IV).
- High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation).
- Severe hepatic impairment defined as ALT >2x ULN or AST >2x ULN (ULN = Upper Limit of Normal).
- Severe renal impairment defined as serum creatinine >1.5x ULN.
- History of severe asthma or chronic obstructive pulmonary disease (COPD).
- History of coagulopathy or systemic bleeding disorder.
- Leukopenia (<2 × 10⁹/L) or thrombocytopenia (<100 × 10⁹/L).
- Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation \[minimally invasive or conventional\], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment.
- Pre-stroke modified Rankin Scale (mRS) score >2.
- Presence of other severe disease resulting in a life expectancy of less than 1 year.
- Inability to understand the study procedures and/or complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders.
- Women who are pregnant or lactating.
- Participation in another clinical trial within the past 3 months or current participation in another clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
On the basis of best medical management, 2 MHz non-invasive ultrasonic scalpel was used for intervention within 48-72 hours after the occurrence of intracerebral hemorrhage, 20min/ day, and continued for 7 days.
On the basis of best medical management, a sham non-invasive ultrasonic scalpel (simulating real treatment with zero energy output) was applied within 48-72 hours after the occurrence of intracerebral hemorrhage, 20 min/day for 7 consecutive days
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07246473